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Prion diseases: Transmission from mad cows?
Gareth W. Roberts and Sharon James
Prion diseases in humans show considerable clinical
and pathological heterogeneity. The identification of a
new variant of Creutzfeldt–Jakob disease, and its
interpretation as evidence of transmission of mad cow
disease to man, rely critically on our understanding of
the epidemiology of prion diseases.
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Prion diseases have been much in the news following the
description [1] of what has been claimed to be a new
variant of Creutzfeldt–Jakob disease (CJD), possibly linked
to the recent UK epidemic of ‘mad cow disease’, or bovine
spongiform encephalopathy (BSE). Prion diseases show a
number of well-recognized characteristics, such as rapidly
progressing dementia, myoclonus (seizure involving muscle
spasms) and widespread spongiform degeneration in the
brain. But they also show considerable variation in their
clinical presentation, disease duration and the type and dis-
tribution of brain lesions [2]. About 85 % of human prion
diseases occur sporadically, but there are also inherited
familial forms, such as Gerstmann–Sträussler–Scheinker
(GSS) syndrome, familial CJD and fatal familial insomnia
(FFI), which are genetic diseases associated with mutations
in the prion protein gene. Kuru, which occurs among cer-
tain tribes in New Guinea, is acquired only by transmission
and is believed to be caused by the consumption of
infected human material. Given the known variability of
human prion diseases, how compelling is the evidence that
the recent CJD cases really do reflect a new form of the
disease transmitted from cattle with BSE?
The pathology of prion diseases is characterized by spongi-
form degeneration of regions of the brain, with gliosis and
variable deposition of a protease-resistant isoform of a
normal cellular protein — the prion protein (PrP). The
term ‘prion’, derived from ‘protein infectious agent’, was
coined to reflect the belief that the protein itself, in an
abnormal form, is the transmissible, disease-causing agent
[3]. This belief was based on many studies, primarily with
the sheep prion disease scrapie, which failed to identify
any nucleic acid associated with the infectious agent. The
prion protein was originally identified in the disease-asso-
ciated form (PrPSc), but was subsequently shown to be a
normal cellular protein (PrPC). The most popular current
view is that PrPSc is infectious because small amounts of
the protein in some way induce a conformational change
in PrPC, which thus switches to the pathological isoform
PrPSc. The switch is therefore an autocatalytic process,
and this is thought to precede spongiform degeneration
and be a critical event in disease pathogenesis [3,4].
Indeed, it has been speculated that heritable disease vari-
ability, associated with different ‘strains’ of the infectious
agent, are caused by the self-propagation of protease-resis-
tant PrPSc polymers with distinct conformations (see [5]
for a recent discussion of the nucleated-polymerization
model of PrPSc replication).
Although the physiological function of PrPC is uncertain,
its conservation among mammals implies it does have an
important role. The available evidence suggests that PrPC
is essential for the maintenance of neuronal integrity in
the brain. The normal function of PrP has been addressed
by creating PrPC ‘knockout’ mice, in which the PrP gene
has been inactivated by homologous recombination.
Although PrP is highly conserved and widely expressed
during early embryogenesis, mice homozygous for a dis-
rupted PrP gene initially seemed developmentally and
behaviourally normal. Significantly, they were resistant to
prion disease, fulfilling an important prediction of the
hypothesis that the transmission of prion diseases involves
an interaction between an abnormal, infectious protein
and the normal cellular protein [3].
More recently, however, it has been reported that, as the
PrP mutant mice age, they do show symptoms of neuronal
disease. In particular, they appear to lose cerebellar Purk-
inje neurons and exhibit weakened g-amino-butyric acid
(GABA) receptor-mediated fast neuronal inhibition and
impaired long-term potentiation [6]. These observations
suggest that PrP is necessary for normal synaptic function
and the long-term survival of Purkinje cells. Furthermore,
these mutant mice show behavioural abnormalities resem-
bling those associated with the human prion disease FFI —
they have altered circadian rhythms and abnormally frag-
mented sleep, in addition to being especially susceptible to
sleep deprivation [7].
Although their phenotype mirrors aspects of human prion
diseases, the PrP mutant mice are, as mentioned above,
resistant to infection by the prion disease agent, and they
do not display pathological hallmarks of the disease, such
as spongiform changes or gliosis. Expression of PrPC by the
host is thus necessary for prion disease-induced neurotoxi-
city. This conclusion is further supported by the observa-
tion that, when wild-type tissue was grafted into the brains
of PrP mutant mice, only the graft developed pathological
changes following inoculation with the prion disease agent
[8]. Furthermore, although PrPSc migrated from the graft
into the host brain, it was insufficient to cause any spongi-
form changes or gliosis in the mutant tissue.
All cases of inherited prion disease analysed have been
found to be linked to a point mutation or extra copies of a
repeat sequence within the protein-coding region of the
PrP gene [2,3]. Although the molecular basis of the phe-
notypic variability exhibited by sporadic CJD is largely
unknown, polymorphism at residue 129 — which is either
methionine or valine — of the PrP protein may affect
pathological features of familial prion diseases as well as
susceptibility to sporadic CJD [9].
Two types of PrPSc have been defined by size and glyco-
sylation differences. When passaged in syngeneic animals,
each strain or isolate shows highly preserved characteris-
tics, such as incubation time, the distribution and intensity
of spongiform degeneration, and the pattern of intracere-
bral PrPSc deposition [3,10]. These strain-specific proper-
ties can, however, drastically change if a given PrPSc strain
is passaged in animals with a different PrP genotype.
Even a single amino-acid change in PrP can cause resis-
tance to infection, or lead to disease with a different incu-
bation time and pathology. Heterogeneity of the
infectious PrPSc agent, either in combination with or inde-
pendent of the host’s PrP genotype, may well contribute
to the phenotypic variability of sporadic CJD. 
Homozygosity for valine at the polymorphic residue 129
mentioned above also enhances susceptibility to iatrogenic
CJD via peripheral contamination, for example caused by
injections of contaminated growth hormone. This form of
CJD typically manifests with a cerebellar syndrome similar
to that of kuru and often shows larger PrPSc accumulation
in the cerebellum than in the cerebral cortex. Valine 129
homozygotes with sporadic CJD have been found to
exhibit similar clinical and pathological features, suggest-
ing that this phenotype is not specific to the iatrogenic
form but is associated with either the valine 129 genotype
or the selection of a specific prion strain, or both [10].
The description of ten ‘atypical’ cases of CJD and their
presumptive association with exposure to infected mater-
ial from cows with BSE, has precipitated the recent crisis
in public confidence over the safety of British beef [1].
The cases are characterized by the following features:
disease onset before the age of 40 years; symptoms of a
psychiatric nature, such as depression, aggression and
behavioural disturbance; a relatively long time-course of
disease (a year or more); and an extensive PrP deposition
in plaques throughout the cortex (see Box). All of the
cases identified so far are homozygous for PrP encoding
methionine at residue 129. The atypical nature of these
cases is thought to be a new development — a new ‘strain’
of the disease — and to represent strong evidence that
BSE-infected material can cause CJD
One aspect of these cases that is claimed to be of critical
epidemiological importance is their recent appearance, in
the UK, just a few years after the BSE epidemic — also in
the UK — reached its peak. CJD in young people — those
under the age of 40 years — is extremely rare [1]. In 14
cases of CJD in those aged less than 30 years previously
reported outside the UK, cortical plaques were described
in only one, and in this report the possible diagnosis of
Gerstmann–Sträussler–Scheinker syndrome was sug-
gested. Only one such case was identified in the UK
between 1970 and 1989, and only two patients aged less
than 30 years old were identified in France between 1968
and 1982; one was identified in Japan between 1975 and
1977, and none at all in Israel between 1963 and 1987.
The overall incidence of CJD in the UK rose in the 1990s,
probably because of improved ascertainment of CJD in
the elderly [11], as previously predicted [12]. Might a
similar improved ascertainment, due in part at least to the
publicity surrounding the BSE epidemic, account for the
recently described younger cases of CJD? Scientists at the
CJD Surveillance Unit in Edinburgh argue against the
view that these cases simply reflect increased ascertain-
ment, as they believe their distinctive neuropathological
pattern would have been detected earlier, especially in
patients so young. It is noteworthy, however, that three of
the ten patients were reported to the CJD Surveillance
Unit as suspect CJD cases only after biopsy samples had
been examined. So, in the absence of neuropathological
examination, these cases might not have come to the
attention of the Unit at all.
Detailed clinical documentation of the genetic forms of
CJD has revealed a wide variation in clinical presentation
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WHO case definition of the new CJD variant
• A suspect case shows a psychiatric presentation with anxiety,
depression, withdrawal and other behavioural changes with
progression to neurological abnormalities; onset of a progressive
cerebellar syndrome within weeks or months of presentation;
forgetfulness and other memory impairment, with subsequent
dementia; and myoclonus in the late stages. 
• The electroencephalogram does not show the changes normally
observed in classic CJD. Less common features include early onset
of dysaesthesia in limbs and face, and chorea, extrapyramidal and
pyramidal signs later in the illness. 
• Neuropathological diagnosis is mandatory for confirmation of
possible cases. Confirmatory examination of the brain should show
numerous widespread kuru-type amyloid plaques surrounded by
vacuoles; spongiform changes that are mostly evident in the basal
ganglia and thalamus; and high-density prion protein accumulation
on immunocytochemical analysis, especially in the cerebellum.
of CJD, including depression and personality disorders
and a long time-course of the disease. Sporadic cases with
atypical presentations are very likely to escape clinical
detection and a recent study has suggested that they may
represent a substantial proportion of prion disease patients
[13]. This study showed that 40 % of prion disease cases
identified neuropathologically had been ‘undetected’
during life, and most of these were found retrospectively
to have had an ‘atypical’ presentation, including psychi-
atric symptomatology and a long course of illness,
although none had ‘kuru plaques’. Two of the cases died
aged 40 and 48 years old in 1980 and 1978 [13]. 
These data have helped fuel the debate over the pheno-
typic limits of CJD and the reliability of the epidemiologi-
cal conclusions that can be drawn from studies using a
narrow clinicopathological definition of CJD [12,13]. It
follows that awareness of the phenotypic variability of
CJD, coupled with the enhanced public interest, might
have led to the uncovering of cases which do not conform
to the ‘typical’ CJD straitjacket and which would previ-
ously have passed unreported [13]. It would seem prudent
to reinvestigate, in archival material, the pathological
nature of cases of psychiatric/neurological disorders associ-
ated with an early age (less than 45 years) of death. Confir-
mation of the absence of cases sharing the phenomenology
of the ‘new strain’ of CJD prior to 1986 would enhance our
confidence in the conclusions drawn from the recent
observations. 
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